Bio-Rad Laboratories, Inc. (BIO.B)
NYSE: BIO.B · Real-Time Price · USD
278.21
-3.74 (-1.33%)
Mar 6, 2026, 4:00 PM EST - Market closed
Bio-Rad Laboratories Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 2,583 | 2,567 | 2,671 | 2,802 | 2,923 | Upgrade
|
| Revenue Growth (YoY) | 0.65% | -3.92% | -4.67% | -4.12% | 14.81% | Upgrade
|
| Cost of Revenue | 1,240 | 1,173 | 1,240 | 1,235 | 1,259 | Upgrade
|
| Gross Profit | 1,344 | 1,394 | 1,431 | 1,567 | 1,663 | Upgrade
|
| Selling, General & Admin | 819.8 | 810.2 | 824.2 | 827.8 | 851.02 | Upgrade
|
| Research & Development | 257.6 | 294.3 | 240.9 | 256.9 | 247.34 | Upgrade
|
| Operating Expenses | 1,077 | 1,105 | 1,065 | 1,085 | 1,098 | Upgrade
|
| Operating Income | 266.2 | 289.2 | 365.7 | 482.6 | 564.74 | Upgrade
|
| Interest Expense | -49 | -48.9 | -49.4 | -38.1 | -1.55 | Upgrade
|
| Interest & Investment Income | 95.5 | 82 | 100.9 | 58.1 | 18.9 | Upgrade
|
| Currency Exchange Gain (Loss) | 6.6 | 3.9 | 7.3 | 0.2 | -2.75 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.3 | 3.2 | 4.9 | -5.2 | 0.68 | Upgrade
|
| EBT Excluding Unusual Items | 319 | 329.4 | 429.4 | 497.6 | 580.01 | Upgrade
|
| Merger & Restructuring Charges | -46.1 | -21.8 | -27.9 | - | -64.4 | Upgrade
|
| Gain (Loss) on Sale of Investments | 895.4 | -2,650 | -1,252 | -5,203 | 4,933 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 1.4 | - | Upgrade
|
| Asset Writedown | -172.8 | - | - | - | - | Upgrade
|
| Pretax Income | 995.5 | -2,343 | -850.1 | -4,704 | 5,449 | Upgrade
|
| Income Tax Expense | 235.6 | -498.3 | -212.8 | -1,077 | 1,195 | Upgrade
|
| Net Income | 759.9 | -1,844 | -637.3 | -3,628 | 4,254 | Upgrade
|
| Net Income to Common | 759.9 | -1,844 | -637.3 | -3,628 | 4,254 | Upgrade
|
| Net Income Growth | - | - | - | - | 11.54% | Upgrade
|
| Shares Outstanding (Basic) | 27 | 28 | 29 | 30 | 30 | Upgrade
|
| Shares Outstanding (Diluted) | 27 | 28 | 29 | 30 | 30 | Upgrade
|
| Shares Change (YoY) | -3.31% | -3.41% | -1.93% | -1.40% | 0.16% | Upgrade
|
| EPS (Basic) | 27.85 | -65.36 | -21.82 | -121.79 | 142.61 | Upgrade
|
| EPS (Diluted) | 27.85 | -65.36 | -21.82 | -121.79 | 140.83 | Upgrade
|
| EPS Growth | - | - | - | - | 11.35% | Upgrade
|
| Free Cash Flow | 374.6 | 289.6 | 218.2 | 81.6 | 535.75 | Upgrade
|
| Free Cash Flow Per Share | 13.73 | 10.26 | 7.47 | 2.74 | 17.74 | Upgrade
|
| Gross Margin | 52.01% | 54.30% | 53.56% | 55.93% | 56.91% | Upgrade
|
| Operating Margin | 10.30% | 11.27% | 13.69% | 17.22% | 19.32% | Upgrade
|
| Profit Margin | 29.42% | -71.86% | -23.86% | -129.45% | 145.57% | Upgrade
|
| Free Cash Flow Margin | 14.50% | 11.28% | 8.17% | 2.91% | 18.33% | Upgrade
|
| EBITDA | 431.6 | 440.8 | 511.6 | 619.9 | 702.34 | Upgrade
|
| EBITDA Margin | 16.71% | 17.18% | 19.15% | 22.12% | 24.03% | Upgrade
|
| D&A For EBITDA | 165.4 | 151.6 | 145.9 | 137.3 | 137.6 | Upgrade
|
| EBIT | 266.2 | 289.2 | 365.7 | 482.6 | 564.74 | Upgrade
|
| EBIT Margin | 10.30% | 11.27% | 13.69% | 17.22% | 19.32% | Upgrade
|
| Effective Tax Rate | 23.67% | - | - | - | 21.93% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.